Literature DB >> 2790786

Epidermal growth factor receptor gene expression, protein kinase activity, and terminal differentiation of human malignant epidermal cells.

I King1, A C Sartorelli.   

Abstract

A number of epidermal growth factor (EGF)-resistant clones have been isolated from human epidermoid carcinoma A431 cells (I. King and A. C. Sartorelli, Biochem. Biophys. Res. Commun., 140: 837, 1986). These cells had a higher capacity to enter a pathway of terminal differentiation, as determined by their ability to form cornified envelopes. Thus, after 6 days in culture, 10% of parental A431 cells expressed a differentiated phenotype, while more than 50% of each of the EGF-resistant variants (M1, A5, and A7) formed cornified envelopes. These EGF-resistant clones expressed fewer EGF receptors and had a lower capacity for EGF receptor autophosphorylation than parental A431 cells. Clone M1 had the highest capacity to form cornified cell envelopes and expressed about 10% of the EGF receptor autophosphorylation activity of parental cells. The decrease in the level of EGF receptor autophosphorylation appeared to be due to a decrease in EGF receptor number rather than to a lowering of enzyme activity per se. Southern analysis demonstrated that all of the EGF-resistant variants contained fewer copies of the EGF receptor gene and no apparent gene rearrangement was detected in these variant cells. A corresponding decrease in EGF receptor mRNA was also observed in M1, A5, and A7 cells, with a ratio of 18:1:10:5 for A431, M1, A5, and A7 cells, respectively. In addition, two other malignant epithelial cell lines, SqCC/Y1 and FaDu, contained relatively few copies of EGF receptor genes, had low EGF receptor kinase activity and showed a relatively high capacity to form cornified envelopes. These findings suggest that the level of the EGF receptor was critical to the regulation of the degree of maturation of malignant epidermal cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2790786

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Phosphoproteomic studies of receptor tyrosine kinases: future perspectives.

Authors:  Paul H Huang
Journal:  Mol Biosyst       Date:  2011-12-02

2.  Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095.

Authors:  G Halmos; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

3.  Autocrine and paracrine growth factors in tumor growth: a mathematical model.

Authors:  S Michelson; J Leith
Journal:  Bull Math Biol       Date:  1991       Impact factor: 1.758

Review 4.  Cell, tissue and organ culture as in vitro models to study the biology of squamous cell carcinomas of the head and neck.

Authors:  P G Sacks
Journal:  Cancer Metastasis Rev       Date:  1996-03       Impact factor: 9.264

5.  Growth factors and growth control of heterogeneous cell populations.

Authors:  S Michelson; J T Leith
Journal:  Bull Math Biol       Date:  1993-09       Impact factor: 1.758

6.  Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts.

Authors:  Robert J G Cardnell; Ross B Mikkelsen
Journal:  PLoS One       Date:  2011-05-25       Impact factor: 3.240

7.  In vivo demonstration of an active tumor pretargeting approach with peptide nucleic acid bioconjugates as complementary system.

Authors:  Anna Leonidova; Christian Foerster; Kristof Zarschler; Maik Schubert; Hans-Jürgen Pietzsch; Jörg Steinbach; Ralf Bergmann; Nils Metzler-Nolte; Holger Stephan; Gilles Gasser
Journal:  Chem Sci       Date:  2015-06-17       Impact factor: 9.825

8.  A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity.

Authors:  Xiaoyu Ding; Wanjian Gu; Yujie Zhong; Xiaoyao Hao; Jinyu Liu; Shukai Xia; Lan Luo; Mingjiu Chen; Chunni Zhang
Journal:  EBioMedicine       Date:  2020-09-16       Impact factor: 8.143

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.